Novo's surprising partnerships, disruptive NHS whispers, and a fresh shift in employer economics could redefine the D2C landscape.
Who Wins (and Loses) in Pharma’s Latest GLP-1…
Novo's surprising partnerships, disruptive NHS whispers, and a fresh shift in employer economics could redefine the D2C landscape.